Yasin Keshvargar
  1. Partner

Mr. Keshvargar is a partner in Davis Polk’s Corporate Department in New York, practicing in the Capital Markets Group. He advises domestic and foreign issuers and underwriters on a broad range of transactions, including initial public offerings and other equity offerings, public and private high-yield, investment-grade and convertible debt financings, restructurings and cross-border transactions. He also advises clients ranging from early-stage privately held companies to well-known seasoned issuers on governance, SEC reporting, strategic transactions and other corporate law matters. His practice ranges across a variety of industries, including biotech, consumer and retail, fintech, technology and life sciences and healthcare.

Mr. Keshvargar co-leads Davis Polk’s Coronavirus taskforce.

Work Highlights

Mr. Keshvargar’s recent experience includes the following transactions:

IPOs
  • Initial public offerings by US emerging growth companies, including Atea Pharmaceuticals, Ayala Pharmaceuticals, Beam Therapeutics, Biodesix, Cvent, Dream Finders Homes, Evolent Health, Generation Bio, Jounce Therapeutics, Legend Biotech, Magenta Therapeutics, Ophthotech, Progyny, Solid Biosciences, Stoke Therapeutics and Terns Pharmaceuticals
  • Initial public offerings by foreign private issuer emerging growth companies including Ablynx (Belgium), ADC Therapeutics (Switzerland), Advanced Accelerator Applications (France), Avolon (Ireland), BioNTech, the highest-valued European biotech IPO (Germany), GeoPark (Argentina), Gracell Biotechnologies, the first operating company IPO of 2021 (Cayman Islands), Immunocore (United Kingdom), Innate Pharma (France) and Inventiva (France)
  • Initial public offerings by non-emerging growth companies, including loanDepot, Grupo Aval, the largest U.S. IPO by a Latin American issuer in 2014, and Hudson News
Other Equity Offerings
  • Numerous representations of issuers and placement agents in connection with pre-IPO private placements and cross over rounds, PIPEs, forward sale transactions and ATM programs
  • Completed the largest secondary offering of common stock in history ($16.0 billion common equity offering for a telecommunications company)
  • Follow-on or secondary offerings by Advanced Accelerator Applications, Applied Genetic Technologies, Bioxcel Therapeutics, Cvent, Energizer, Evolent Health, Hilton, PTC Therapeutics, ShakeShack and Southwestern Energy
  • Rights offerings by BioNTech, Liberty Media and a national telecommunications company
Investment- and High-Grade Debt
  • Offerings by Eastman, Heineken, Mylan, Evolent Health, PTC Therapeutics and Walgreens
High-Yield Debt
  • High-yield debt offerings by Adtalem, Energizer, Western Refining, NCI Building Systems, Murphy and XPO Logistics
Convertible Debt
  • Convertible debt offerings by Evolent Health, Integra LifeSciences, Southwestern Energy and PTC Therapeutics

Recognition

  • The National Law Journal “Crisis Leadership Trailblazer,” 2020
  • Chambers Latin America “Associate to Watch” – Capital Markets, 2013 and 2014

Professional History

  • Partner, 2019-present
  • Counsel, 2017-2019
  • Associate, 2008-2017

Bar Admissions

  • State of New York

Education

  • LL.B., King's College London, 2006
    • Clifford Chance Prize for Outstanding Performance
    • first-class honours
  • Master, Law, Université Panthéon-Sorbonne - Paris 1, 2006
  • LL.M., Harvard Law School, 2008

Languages

  • French
  • Arabic